Agios Pharmaceuticals
Small-molecule metabolic medicines for rare blood disorders
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2007
- Latest Form D
- $78M, Nov 2011
- Total capital
- $86.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $86.8M
- 2 Form D · last Nov 2011
- 179 months since last filing
- Federal contracts
- $73K
- 1 award · Veterans Affairs
- Rank in Biotech#342 of 4373
- Granted patents
- 1
- 23 pending · first 2025
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Federal contractVeterans Affairs · Pharmaceutical Aqvesme - 3 Month Supply.$73K
- Private capital raisedForm D · SEC · 2nd filing$78M
- Private capital raisedForm D · SEC · 1st filing$8.8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- David SchenkeinExecutive Officer, DirectorNamed in SEC Form D filings
- Doug ColeDirectorNamed in SEC Form D filings
- Duncan HiggonsExecutive OfficerNamed in SEC Form D filings
- John C. MaraganoreDirectorNamed in SEC Form D filings
- Kevin C. StarrDirectorNamed in SEC Form D filings
- Lewis C. CantleyDirectorNamed in SEC Form D filings
Show all 9 people
- Marc C. Tessier-LavigneDirectorNamed in SEC Form D filings
- Perry C. KarsenDirectorNamed in SEC Form D filings
- Robert NelsenDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 24- PendingBCAT2 InhibitorsUSPTOApplication 18709121
- PendingMethods Of Using Pyruvate Kinase ActivatorsUSPTOApplication 19306156
- PendingPyruvate Kinase Activators For Use In TherapyUSPTOApplication 19263173
Show all 24 patent records
- BCAT2 InhibitorsJun 11, 2026 · Application 18709121Pending
- Methods Of Using Pyruvate Kinase ActivatorsDec 25, 2025 · Application 19306156Pending
- Pyruvate Kinase Activators For Use In TherapyOct 30, 2025 · Application 19263173Pending
- Compounds And Methods Useful For Stabilizing Phenylalanine Hydroxylase MutationsOct 16, 2025 · Application 18841476Pending
- Therapeutic Compounds And CompositionsSep 30, 2025 · US 12,428,376Granted
- Compounds And Methods Useful For Stabilizing Phenylalanine Hydroxylase MutationsAug 21, 2025 · Application 18841478Pending
- Compounds And Methods Useful For Stabilizing Phenylalanine Hydroxylase MutationsMay 29, 2025 · Application 18841480Pending
- Pyruvate Kinase Activators For Use In Treating Blood DisordersMay 8, 2025 · Application 18882884Pending
- Compounds For Treating Mds-associated Anemias And Other ConditionsApr 3, 2025 · Application 18711090Pending
- Compounds And Methods Useful For Stabilizing Phenylalanine Hydroxylase MutationsMar 6, 2025 · Application 18818695Pending
- Mitapivat Therapy And Modulators Of Cytochrome P450Mar 6, 2025 · Application 18917603Pending
- Methods For Titrating MitapivatJun 27, 2024 · Application 18288888Pending
- Porphyria Disease ModelsApplication PCTUS2023077268Pending
- Use Of A Pyruvate Kinase Activator In The Treatment Of Renal Fibrosis And Other Renal DiseasesApplication PCTUS2025052653Pending
- Use Of A Pk Activator In The Treatment Of Sickle Cell DiseaseApplication PCTUS2025021249Pending
- Use Of A Pyruvate Kinase Activator In The Treatment Of Renal Fibrosis And Other Renal DiseasesApplication 63712869Pending
- Compounds And Methods Useful For Stabilizing Phenylalanine Hydroxylase MutationsApplication PCTUS2024044303Pending
- Compounds And Methods Useful For Stabilizing Phenylalanine Hydroxylase MutationsApplication PCTUS2024044308Pending
- Use Of A Pk Activator In The Treatment Of Sickle Cell DiseaseApplication 63684515Pending
- Synthesis Of Pyruvate Kinase ActivatorsApplication PCTUS2024036849Pending
- BCAT2 InhibitorsApplication PCTUS2024029738Pending
- Crystalline Forms Of 2-((1H-PYRAZOL-3-YL)METHYL)-6-((6-AMINOPYRIDIN-2-YL)METHYL)-4-METHYL-4,6-DIHYDRO-5H-THIAZOLO[5',4':4,5]PYRROLO[2,3-D]PYRIDAZIN-5-ONEApplication PCTUS2024029471Pending
- Use Of A Pk Activator In The Treatment Of Sickle Cell DiseaseApplication 63570365Pending
- BCAT2 InhibitorsApplication 19483686Pending
Related companies, and why
- PRIMETIME LIFE SCIENCES, LLCSimilar federal contract value in Biotech · $79K in contracts
- Nexome Genomics Inc.Similar federal contract value in Biotech · $78K in contracts
- ORA BIOMEDICAL, INC.Similar federal contract value in Biotech · $75K in contracts
- BIOLYTIC LAB PERFORMANCE, INC.Similar federal contract value in Biotech · $72K in contracts
- ARDELYX, INC.Similar federal contract value in Biotech · $72K in contracts
- ATELERIX LIFE SCIENCES INCSimilar federal contract value in Biotech · $68K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .